Law360, New York (March 28, 2012, 1:13 PM EDT) -- In a speech given Nov. 12, 2009, in front of an audience of large pharmaceutical and device company attorneys, compliance officers and executives, Lanny Breuer, assistant attorney general in the U.S. Department of Justice Criminal Division’s Fraud Section stated that the application of the Foreign Corrupt Practices Act to the pharmaceutical industry would be “one area of criminal enforcement that will be a focus for the Fraud Section in the months and years ahead.”
Sure enough, within several months, more than five pharmaceutical and device companies reported in their 10-K filings that they had received “letters of inquiry” from the DOJ...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!